Castlight Health Inc (NYSE:CSLT) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,630,000 shares, a decline of 13.8% from the December 15th total of 1,890,000 shares. Based on an average trading volume of 796,300 shares, the short-interest ratio is currently 2.0 days. Approximately 1.6% of the company’s shares are sold short.

Castlight Health stock traded down $0.08 during trading on Tuesday, reaching $1.41. 778,771 shares of the company’s stock were exchanged, compared to its average volume of 1,101,208. The company’s 50-day moving average is $1.31 and its two-hundred day moving average is $1.69. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.84 and a current ratio of 1.84. Castlight Health has a 52-week low of $1.01 and a 52-week high of $4.15. The firm has a market cap of $197.33 million, a price-to-earnings ratio of -8.81 and a beta of 1.51.

Castlight Health (NYSE:CSLT) last announced its quarterly earnings results on Thursday, October 24th. The software maker reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). Castlight Health had a negative net margin of 21.68% and a negative return on equity of 13.00%. The firm had revenue of $35.46 million during the quarter, compared to analysts’ expectations of $35.46 million. Castlight Health’s revenue for the quarter was down 11.4% on a year-over-year basis. Analysts anticipate that Castlight Health will post -0.21 EPS for the current year.

Several analysts have recently issued reports on CSLT shares. ValuEngine raised shares of Castlight Health from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Wells Fargo & Co cut shares of Castlight Health from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $1.75 to $1.20 in a research note on Wednesday, January 8th. Canaccord Genuity lowered their price objective on shares of Castlight Health from $4.00 to $1.50 in a research note on Wednesday, November 27th. Finally, Zacks Investment Research raised shares of Castlight Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. Castlight Health currently has an average rating of “Hold” and a consensus target price of $2.07.

In other news, President Mangini Siobhan Nolan sold 31,656 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $1.34, for a total transaction of $42,419.04. Following the completion of the sale, the president now directly owns 320,556 shares of the company’s stock, valued at approximately $429,545.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Maeve O’meara sold 51,482 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $1.34, for a total transaction of $68,985.88. Following the sale, the chief executive officer now directly owns 297,638 shares of the company’s stock, valued at $398,834.92. The disclosure for this sale can be found here. Insiders sold a total of 158,059 shares of company stock valued at $210,265 over the last quarter. 17.37% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in CSLT. Metropolitan Life Insurance Co NY purchased a new stake in Castlight Health during the 1st quarter worth $97,000. JPMorgan Chase & Co. boosted its position in Castlight Health by 44.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,652 shares of the software maker’s stock worth $82,000 after purchasing an additional 8,491 shares during the period. Prudential Financial Inc. boosted its position in Castlight Health by 27.3% during the 2nd quarter. Prudential Financial Inc. now owns 41,204 shares of the software maker’s stock worth $133,000 after purchasing an additional 8,840 shares during the period. Russell Investments Group Ltd. boosted its position in Castlight Health by 6.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 370,034 shares of the software maker’s stock worth $1,193,000 after purchasing an additional 20,938 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in Castlight Health by 12.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 478,268 shares of the software maker’s stock worth $1,545,000 after purchasing an additional 53,485 shares during the period. 55.96% of the stock is owned by hedge funds and other institutional investors.

Castlight Health Company Profile

Castlight Health, Inc provides a software-as-a-service platform used for health benefits navigation for employees in the United States. Its platform matches employees to the resources their employers make available to them; managing a condition; and assists them to manage their benefits. The company also offers implementation, user and customer support, and marketplace services.

Recommended Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Castlight Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castlight Health and related companies with MarketBeat.com's FREE daily email newsletter.